Kornimate/medical-research-clean huggingface dataset:
effect of dexmedetomidine on levels of plasma inflammatory factor in asthma patients undergoing general anesthesia

Conditions: Anesthesia; Asthma

Summary: the study try to illustrate the possible mechanisms of tending to induce airway spasms and the impact of dexmedetomidine on inflammatory reaction in general anesthesia patients with asthma，by detecting the differences of plasma inflammatory factor interleukin(il)-4, il-5, il-13, il-17, il-33, mbp and immunoglobulin e(ige) levels between asthma patients and non-asthma patients.


Eligibility criteria:
inclusion criteria: * obtain informed consent * elective general anesthesia surgery, surgery time 1 \~ 3 hours. * 20 patients with a history of asthma. * 60 patients with no history of asthma. * american society of anesthesiologists (asa)classification:class i\~ii. * aged between 18 and 65 years old. exclusion criteria: * sbp≥180 mmhg or \<90 mmhg, dbp≥110 mmhg or \<60 mmhg. * serious heart, brain, liver, kidney, lung, endocrine diseases or serious infections. * hematopoietic dysfunction or bleeding tendency and hemorrhagic disease. * a neuromuscular system disease. * airway and lung surgery. * predict possible or happened difficult airway. * immune function defect. * sure/suspected abuse of narcotic analgesics or drugs or alcohol dependence. * the test drug allergy or have other contraindications in patients. * childbearing age women not to take appropriate contraception, pregnancy or lactation. * participated in other clinical drug research in the last 30 days.

Keywords: dexmedetomidine inflammatory factor inflammatory mediator cytokines asthma
primary antimicrobial resistance patterns of austrian helicobacter pylori clinical isolates

Conditions: Helicobacter Pylori Infection

Summary: helicobacter pylori infects \~ 50% of the world's population and a quarter of the european population. h. pylori is responsible for a large proportion of gastric and duodenal ulcers and gastritis. chronic infection with h. pylori is a risk factor for the development of stomach cancer and malt (mucosa-associated lymphoid tissue) lymphoma. the prospects of success for an antimicrobial eradication therapy is drastically reduced by the significant increase in antibiotic resistance in austrian h. pylori isolates. the currently available data were obtained however from narrowly defined geographical regions and the clinical routine without information on patient selection. we suspect a considerable geographical variability of resistance patterns and a clinical bias for a preferential investigation of patients with unsuccessful, empirical eradication therapy. the objective of the proposed study is therefore an austria-wide collection of data on h. pylori resistance in a prospective clinical study. the data thus collected will enable a significant improvement in current treatment recommendations.


Eligibility criteria:
inclusion criteria: * undergoing a diagnostic gastroscopy for the first time in their lives or had a diagnostic gastroscopy for any reason \>10 years ago * older than 18 years of age * written informed consent exclusion criteria: * previous h. pylori eradication therapies * antimicrobial treatment for other reasons than h. pylori eradication within 3 months prior to gastroscopy
efficacy and safety of olmesartan medoxomil in stage 1 and 2 essential hypertension

Conditions: Essential Hypertension

Summary: in patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine.


Eligibility criteria:
inclusion criteria: * stage 1 and 2 hypertension without treatment for at least 2 weeks * women with no risk of becoming pregnant exclusion criteria: * study participation could result in risk to health of subject * cardiovascular disease * secondary hypertension or stage 3 hypertension * myocardial infarction within the last 6 months * congestive heart failure * pulmonary edema * valvular alterations or rheumatic cardiopathy * clinically relevant conduction disorders significant arrhythmias * alcohol or illicit drug use * medication abuse * pregnant or nursing women

Keywords: hypertension angiotensin ii type 1 receptor blocker olmesartan
surufatinib combined with serplulimab and standard chemotherapy as first-line treatment in advanced solid tumors with neuroendocrine differentiation

Conditions: ESCC; Biliary Tract Cancer; Gastric Cancer; Pancreas Cancer

Summary: currently, there are no standard treatment and relevant exploration for solid tumors patients with ned. the study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment ofadvanced solid tumors with ned, in order to provide a new treatment option for advanced solid tumors patients with ned.

this is a single-arm, multi-cohort, open-label, single-center, prospective, exploratory clinical study. we planned to enroll 80 patients who would receive surufatinib plus tislelizumab until disease progression, intolerance, or withdrawal of consent. the study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment of advanced solid tumors with ned, in order to provide a new treatment option for advanced solid tumors patients with ned.

Eligibility criteria:
inclusion criteria: * histopathologically confirmed locally advanced or metastatic unresectable escc, btc, pc or gc with an abnormal ned or ne phenotype (without neuroendocrine morphologic features and positive immunohistochemical expression of at least one neuroendocrine marker (cga, syn)); * have at least one measurable lesion according to recist v1.1; * ecog performance status: 0-1; * no previous systemic therapy; * urine protein\< ++ . if urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g; * expected survival time \&gt; 3 months; exclusion criteria: * have uncontrolled hypertension, defined as systolic blood pressure \&gt;150 mmhg or diastolic blood pressure \&gt;90 mm hg, while under anti-hypertension treatment; * with active bleeding or bleeding tendency; * severe history of cardiovascular and cerebrovascular diseases; * other malignancies diagnosed within the previous 5 years, except basal cell carcinoma or cervical carcinoma in situ after radical resection.

Keywords: surufatinib neuroendocrine differentiation
nature as a buffer among people with chronic pain

Conditions: Chronic Pain

Summary: this randomized controlled trial examines the effect of nature exposure on pain intensity levels among older adults who experience chronic pain. investigators examine the effects of nature on: the experience of chronic pain, on pain catastrophizing, and on attention restoration.

nature has been used to reduce pain in the context of acute pain (e.g., during painful medical procedures) but nature has not been examined as an intervention strategy to address chronic pain. second, the mechanism though which nature might reduce the experience of pain is not well understood. participants are cognitively intact individuals aged 60-90 who experience chronic pain and who rate their health as fair, good or excellent. participants are randomly assigned to one of three conditions: virtual reality (vr) nature; vr built environment; or control. researchers examine effects of vr nature exposure on the experience of chronic pain, pain catastrophizing, and on attention restoration as well as the relations among these variables.

Eligibility criteria:
inclusion criteria: * rate health as "fair" "good" or "excellent" * experience chronic pain * cognitively intact * do not use wheelchair exclusion criteria:

Keywords: environment nature
ultrasound guided quadratus lumborum block versus caudal block in pediatric patient

Conditions: Postoperative Pain

Summary: the purpose of this research study is to find the best way to decrease pain in children whom have had low abdominal surgery. investigators will perform two technique;caudal block or quadratus lumborum block .the method used is often chosen by which one the doctor has more experience using. the investigator plans to find out if one of the methods is more effective and/or safer than the other method. the results of this study will help learn how to best control pain in children having surgery low abdominal surgery.

children aged 1-9 years undergoing lower abdominal surgeries would be recruited in this randomized study. children would be monitored by electrocardiogram, pulse oximeter and non-invasive blood pressure. after preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. then laryngeal mask is inserted when conditions are satisfactory (jaw relaxed, lash reflex disappeared, no coughing, gagging, swallowing).after ethical committee approval, informed written consent will be obtained from all patients. consenting patients scheduled to have unilaterally low abdominal surgery(inguinal hernia,hydrocele,undescended testicles surgery will be randomised to unilateral quadratus lumborum block or caudal block at the begin of surgery. all patients heart rate,map and oxygen saturation record intraoperatively. all patients will receive paracetamol if requirement for postoperative analgesia.all patient will transfer from pacu to day-surgery unit (dsu) if they achieved modified aldrete score of ten. all patients will be assessed postoperatively by a blinded investigator: in the postanesthesia care unit and at 30 min 1,2, 4, 6, 12, 24, hour postoperatively.flacc and modified children's hospital of eastern ontario pain scale (cheops) score will be used.

Eligibility criteria:
inclusion criteria: 1. age 1-9 2. asa physical status i-ii 3. undergoing unilateral low abdominal surgery exclusion criteria: 1. history of developmental delay or mental retardation, which will make observational pain intensity assessment difficult 2. parent refusal 3. history of allergic reactions to local anesthetics 4. rash or infection at the injection site 5. anatomical abnormality 6. bleeding diatheses 7. coagulopathy, 8. history of diseases 1. renal 2. hepatic 3. cardiac 4. upper or lower airway 5. neurological
high versus low level of lumbar traction in acute lumbar sciatica due to disc herniation

Conditions: Acute Lumbar Sciatica Secondary to Disc Herniation

Summary: the aim of this study is to compare two levels (high and low forces) of short term lumbar traction on pain and functional tests of the lower limbs in a specific population of patients presenting with acute lumbar sciatica secondary to disc herniation. the investigators hypothesize that, in this particular medical condition, high level of lumbar traction might be more effective than low level lumbar traction in decreasing the pain associated with acute sciatica.


Eligibility criteria:
inclusion criteria: * less than 6-week lumbar sciatica secondary to disc herniation, confirmed by pain radiating down the leg along the distribution of the sciatic nerve together with positive straight leg raising test (slrt) exclusion criteria: * symptoms persisting for more than 6 weeks * signs of clinical neurological deficit * lumbar sciatica not caused by disc herniation * presence of lumbar tomodensitometry abnormalities * subjects younger than 18 * pregnant women * patients on medical leave for more than 3 weeks at inclusion * patients with history of lumbar surgery * patients who already had lumbar traction therapy

Keywords: acute lumbar sciatica, lumbar traction, traction force, radicular pain, lumbar functional parameters, disc herniation
a study to compare the effects of different sized particles on cells in the nose

Conditions: Hypersensitivity, Immediate; Atopic Hypersensitivity

Summary: the goal of this study is to see how the type and size of particles found in air pollution affects inflammation in the nose in people who are skin test positive to at least one allergen. it has been observed that pollution makes allergies worse. it has also been suggested that very small particles may affect allergies more than larger particles.

cough, bronchitis, asthma, and chronic obstructive pulmonary disease are all associated with elevated pollution particle levels. researchers believe that particulate pollutants can exacerbate allergy and inflammation and affect asthma and allergy prevalence. in an urban setting such as the los angeles basin, particles generated by vehicular traffic are thought to be important risk factors. recently, the environmental health centre of southern california confirmed that there is a strong association between traffic near homes and schools and development of asthma. this study will help researchers describe the effects of various size pollution particles in causing inflammation in the nose. there will be a total of 20 study visits. the study procedures include physical exams, symptom score for nose, nose washes and nose challenges with particulate matter. the particulates will be given in a random order and include the following: saline (sterile salt water), inert carbon particles (carbon black), diesel exhaust particles (dep), small (fine) particles or very small (ultrafine) particles. these last two (fine and ultrafine) particles are obtained from concentrated normal los angeles air. the particulate will be sprayed into the nose with a standard nasal spray.

Eligibility criteria:
inclusion criteria: * previously determined high inflammatory responders to diesel exhaust particles * previously determined atopy as demonstrated by allergy skin testing * asymptomatic on day of challenge. exclusion criteria: * history of lung problems (including asthma), bleeding, neuromuscular, liver, kidney or heart disorders. * history of anaphylaxis. * recent upper respiratory infection (less than 4 weeks prior to study) or other active infection. * active smoker or smoker in the past 2 years. * treatment with topical nasal steroids (\< 1 month), systemic steroids (\<1 month), oral antihistamines (\< 1 week) prior to any nasal challenge. * use of leukotriene receptor antagonist (\< 1 month ) prior to any nasal challenge * intranasal antihistamine or cromolyn use \< 1 week prior to any nasal challenge . * history of treatment with allergy immunotherapy. * inability to perform nasal lavage. * inability to give written informed consent * pregnancy

Keywords: vehicle emissions diesel exhaust
the epidural anesthesia on the intra-operative and post-operative amount of bleeding post lower limb salvage surgery

Conditions: Bone Tumor

Summary: epidural anesthesia is a very useful tool in lower limb salvage surgery, which helps pain control intra and more importantly post-operative pain. it is a well-known effect of epidural injections to cause a sympathetic stimulation and consequently vasodilatation in the lower limb vessels. since epidural catheters can cause vasodilatation in lower limb vessels, they can subsequently lead to increased intra and post-operative bleeding from the surgical wound. the study will involve all patients having a bone tumor in the lower limb and subjected to tumor resection and reconstruction by prosthesis. the patient will be randomized according to the administration of epidural anesthesia into two arms, an arm in which epidural anesthesia was employed and another arm in which the patient was subjected only to general anesthesia and the amount of intra and postoperative bleeding will be compared in both arms.

assessment of intra-operative bleeding will be based upon weighing and counting of the blood soaked dressing and the amount of blood transfusion used. assessment of post-operative bleeding will be based upon the amount of blood collected from the suction drain and amount of blood transfusion. all patient subjected to anticoagulant post-operative or another type of surgery other than implantation of prosthesis will be excluded from the study.

Eligibility criteria:
inclusion criteria: * lower limb bone tumor * reconstruction by prosthesis exclusion criteria: * upper limb and pelvic salvage surgery. * other methods of reconstruction than prosthesis * use of tourniquet intra-operative. * post-operative anticoagulation.
colonoscopy and antiplatelet therapy trial

Conditions: Coronary Arterial Disease (CAD); Peripheral Vascular Disease

Summary: patients on dual antiplatelet therapy )aspirin plus a p2y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. patients are ussually asked to stop the p2y12 inhibitor for the procedure. currently, recommendation is that patients only on a p2y12 inhibitor be changes to aspirin for the procedure. this pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a p2y12 inhibitor. patinets who participate will randomly be randomly asked to stop either aspirin or the p2y12 inhibitor 1 week before the procedure. periprocedural bleeding and bleeding after the procedure for iup to 30 days.


Eligibility criteria:
inclusion criteria: 1. age ≥ 45 years 2. stable patients defined as having angina ccs (canadian cardiovascular society) class 1-3 and/or heart failure nyha class 1-2 without a change in guideline directed anti-ischemic or heart failure medications within 30 days prior to randomization. 3. patients with cardiovascular disease defined as coronary artery disease, cerebrovascular disease or peripheral vascular disease taking dapt (defined as aspirin plus a p2y12 inhibitor). the decision to use dapt in this patient will be made by the managing physician(s) before recruitment for this study. consider replacing last statement with "as directed by their physician prior to recruitment into this study" 4. scheduled for elective screening or surveillance outpatient colonoscopy exclusion criteria: 1. coronary intervention (pci or cabg) less than 90 days prior to randomization 2. acs event in less than 90 days prior to randomization 3. transient ischemic attack (tia) and/or stroke event in less than 90 days prior to randomization 4. acute limb ischemia and/or amputation in less than 90 days prior to randomization 5. post cardiac valve replacement (either percutaneous or surgical) 6. high cardiovascular risk: 1. patients with ccs class 4 angina 2. hospitalized with acs within 1 month prior to randomization 3. patients undergoing pci or cabg within the 3 months prior to randomization 7. patients on left ventricular assist device (lvad) or post cardiac transplantation 8. patients with nyha class 3 or 4 heart failure 9. any condition requiring treatment requires chronic use of an anticoagulant. 10. chronic kidney disease stage 5 (with or without dialysis) 11. liver cirrhosis with platelet count \&lt; 50,000/ mm3 and/or inr \&gt;1.4 12. hematocrit \&lt; 30% and hemoglobin \&lt; 10 mg/dl 13. emergent or inpatient colonoscopy

Keywords: colonoscopy antiplatelet therapy
osteoconduction potential of an injectable calcium phosphate in orthopaedic surgery in fillings of osseous defects

Conditions: Grafting, Bone

Summary: the purpose of this non-comparative study is to test, for the first time, the bioactivity of a new "ready to use" calcium phosphate biomaterial in fillings of little losses of osseous substance from various origins, such as traumatic and benign tumoral causes.

a lot of osseous substitution products were already used to fill osseous defects in order to prevent losses of osseous that are envisaged and so prejudicial. synthetic calcium phosphate ceramics (particularly granulated forms) already has shown their osteoconduction potential in human at different sites. but it is difficult to put these granules in very little place. the injectable form of calcium phosphate granules "ready to use" is easier to be used and allow a diminution of the risk of infection during surgery, and permit homogeneity of the biomaterial. injectable form of calcium phosphate granules did already has shown his biocompatibility and biofunctionality in animals. the purpose of this study is to study the biocompatibility and biofunctionality of this biomaterial in his injectable form in fillings of little losses of osseous substance from various origins were no charge will act to the biomaterial.

Eligibility criteria:
inclusion criteria: * medium osseous defects (inferior to 20 cc) without articular communication * patients without a personal medical history of bone infection, cancer, diabetes, tuberculosis, and in general, any pathology which could interfere with the results of the study or expose the patient to additional risk * patients without drepanocytosis, or congenital or acquired immunizing deficit * patients who have the benefit of a social security system, a previous medical exam and who were informed and gave free consent about this study exclusion criteria: * proven nicotinism and alcoholism * pregnant or nursing women * patients who received another study drug or another study device in the past 3 months or patients who will be included in another clinical study * if postoperative follow-up for a patient is considered to be random by the investigator, he/she should not be included

Keywords: bone substitutes bone replacement materials bone void filler grafting, bone bone cysts
evaluation of the effectiveness of prepectoral breast reconstruction

Conditions: Breast Cancer

Summary: the study plans to compare conventional submuscular reconstruction with definitive implant and muscle sparing reconstruction with definitive implant in selected patients. the two techniques are compared in terms of patient quality of life and satisfaction; patient related outcomes, reconstruction morbidity, early and late complications are also investigated.

the study plans to compare conventional submuscular reconstruction with definitive implant and muscle sparing reconstruction with definitive implant in selected patients. the two techniques are compared in terms of patient quality of life and satisfaction; patient related outcomes, reconstruction morbidity, early and late complications are also investigated. the study plans to collect robust data to support the prepectoral implant placement and complete coverage of implant with acellular dermal matrix in the clinical practice. consequently, the project plans to move toward evidence-based medicine in breast reconstruction, avoiding marketing influences and surgeon experience as the sole source of evidence.

Eligibility criteria:
inclusion criteria: 1. informed consent 2. not smokers 3. no vascular comorbidities (diabetic, vasculitis, coagulation disorders) 4. bmi\<30 5. cup b-c (or mastectomy estimated weight less than 550gm) 6. good subcutaneous layer (\>1cm on pinch test measured in upper/medial quadrant) 7. no previous breast surgery 8. no previous breast irradiation 9. breast ptosis 1-2 according to renault's classification 10. dcis tumors 11. t1 t2 pn0 breast tumor with known favourable biologic features exclusion criteria: 1. impossibility of immediate reconstruction with definitive implants due to inadequacy of mastectomy flaps (inadequate in quantity and/or quality) 2. positive sentinel node biopsy requiring complete axillary dissection
fatigue and kinematics during isometric activity of the upper limbs in young and older adults

Conditions: Fatigue

Summary: the aim of this study is to understand the relationship between perceived effort and physiological and kinematic variables caused by isometric activity of the upper limbs, as well as its relationship with socio-demographic characteristics, level of activity and quality of life.


Eligibility criteria:
inclusion criteria: * healthy * minimum age of 18 years; exclusion criteria: * unable to provide written consent * history of heart, cardiovascular and / or respiratory disease, * known untreated hypertension, cardiomyopathy, or exercise intolerance * presence of cognitive or neurological disorders * neuromuscular or orthopaedic disorder that limits the movement of the upper limb to 90° flexion or the maintenance of that position * bmi ≥ 40

Keywords: respiration perceived kinematics performance